Saltar al contenido
Merck

1457301

USP

Naproxen

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
CH3OC10H6CH(CH3)CO2H
Número de CAS:
Peso molecular:
230.26
Beilstein/REAXYS Number:
3591068
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

naproxen

manufacturer/tradename

USP

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

152-154 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O

InChI

1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

InChI key

CMWTZPSULFXXJA-VIFPVBQESA-N

Gene Information

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Dexamethasone Compounded Oral Suspension
  • Naproxen
  • Naproxen Compounded Oral Suspension
  • Naproxen Delayed-Release Tablets
  • Naproxen Oral Suspension
  • Naproxen Tablets
  • Terazosin Tablets

Biochem/physiol Actions

Inhibidor no selectivo de la ciclooxigenasa (COX-1 y COX-2).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Marta L Capone et al.
Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)
We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5
Larisa Kovacevic et al.
Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)
A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4
Chuthamanee C Suthisisang et al.
Headache, 50(5), 808-818 (2010-03-20)
To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks. Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have
Christopher Derry et al.
The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)
Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg
Anke Prudic et al.
Molecular pharmaceutics, 11(11), 4189-4198 (2014-10-09)
The incorporation of poorly soluble active pharmaceutical ingredients (APIs) into excipients (e.g., polymers) to formulate an amorphous solid dispersion is a promising strategy to improve the oral bioavailability of the API. The application of copolymer excipients allows access to combinations

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico